The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.a

Bronchospasm - Wheezing - Asthma

Publications

Rouzaud P, Estivals M, Pujazon MC, Carles P, Lauque D

[Respiratory complications of the vinorelbine-mitomycin combination].

Revue des maladies respiratoires 1999 Feb;16;81-4 — 1999 Feb — 81-4

Raderer M, Kornek G, Hejna M, Vorbeck F, Weinlaender G, Scheithauer W

Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C.

Annals of oncology : official journal of the European Society for Medical Oncology 1996 Nov;7;973-5 — 1996 Nov — 973-5

Rivera MP, Kris MG, Gralla RJ, White DA

Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy.

American journal of clinical oncology 1995 Jun;18;245-50 — 1995 Jun — 245-50

Luedke D, McLaughlin TT, Daughaday C, Luedke S, Harrison B, Reed G, Martello O

Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression.

Cancer 1985 Feb 01;55;542-5 — 1985 Feb 01 — 542-5